On May 30, 2024, the California Institute for Regenerative Medicine (CIRM) announced it had awarded $53 million to fund various projects from its Clinical and Translation programs aimed at preventing heart failure to the advancement of cell therapy for Parkinson’s disease and the targeting of numerous cancers. 

Among the awards were two preclinical projects in the Agency’s clinical program, which provides funding for eligible stem cell and gene therapy-based projects through all stages of clinical trial development.